The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer therapy. Disruptions in Met downregulation have been associated with aggressive tumor progression with several therapeutic strategies addressing this aspect of Met biology. Castias B-lineage lymphoma (Cbl) E3 ligase-mediated degradation, which attenuates Met signaling via ligand-dependent Met internalization, is a major negative regulator of Met expression. It is believed that one of the mechanisms by which the therapeutic anti-Met antibodies induce cancer cell death in Met overexpressing tumors is via internalization and subsequent degradation of Met from the cell surface. However, a previously reported Met-targeting antibody demonstrated intrinsic agonistic activity while being capable of inducing Cbl-mediated degradation of Met, suggesting that Cbl-mediated degradation requires receptor activation and impedes therapeutic application. We have developed a potent and selective bivalent Met-targeting antibody (SAIT301) that invokes Met degradation using an alternative regulator LRIG1. In this report, we demonstrate that LRIG1 mediates degradation of Met by SAIT301 and this degradation does not require Met activation. Furthermore, SAIT301 was able to downregulate Met and dramatically inhibit growth of tumors with low or no Cbl expression, as well as tumors with Met exon 14 deletion that prevents Met binding to Cbl. In summary, we demonstrate the enhanced therapeutic potential of a novel tumor-inhibiting anti-Met antibody, SAIT301, which utilizes a Cbl-independent, LRIG1-mediated Met degradation pathway and thereby avoids the agonism that limits the effectiveness of previously reported anti-Met antibodies.
INTRODUCTION
Met, the receptor tyrosine kinase (RTK) for its physiological ligand hepatocyte growth factor/scatter factor (HGF/SF), is expressed predominantly in cells of epithelial origin.
1,2 Upon binding with HGF/SF, cell surface Met homodimerizes, leading to activation of its intracellular tyrosine kinase domain, as well as the autophosphorylation of several tyrosine residues including Y1003, Y1349 and Y1356. [3] [4] [5] Phosphorylated carboxy-terminal substrate-binding site of Met allows the recruitment of several adapter proteins to initiate downstream signaling such as PI3K/Akt and Ras/MAPK pathways. Y1003-phosphorylated Met is able to recruit the castias B-lineage lymphoma (Cbl) E3 ubiquitin ligase, promoting ligand-induced receptor ubiquitination and subsequent Met degradation. 6 In conclusion, HGF/SF binding triggers activation of oncogenic signaling pathways and concurrent degradation of Met receptor as a negative feedback mechanism.
Cbl is known to be a major negative regulator of RTKs, including Met. Cbl mutations have been reported recently in a variety of solid tumors. 7, 8 Splice and somatic mutants of the Met receptor, which lead to loss of the Cbl binding site in juxtamembrane domains, have been identified in human gastric and lung cancers and are attributed to Met activation and aggressive tumor growth. 9, 10 Loss of Cbl function and mutant Met exhibit decreased ubiquitination and delayed downregulation correlating with elevated levels of Met protein. 11, 12 As a consequence, these naturally occurring mutant receptors are poorly ubiquitinated and not targeted for degradation. In addition, Cbl is also an important mediator of EGFR and Met crosstalk during tumorigenesis. In gastric cancers, Met overexpression leads to the depletion of Cbl; the subsequent reduction in EGFR downregulation results in enhanced EGFR signaling. 13, 14 In a number of tumor types, aberrant activation of Met signaling is associated with tumorigenesis and metastasis, mainly through receptor overexpression. [15] [16] [17] [18] Furthermore, Met has emerged as a key factor in resistance to EGFR and VEGF-targeted therapies. 19, 20 Therefore it is crucial to understand the underlying mechanisms controlling Met expression to target Met for therapeutic interventions. [21] [22] [23] [24] [25] Although Met constitutes an attractive cancer therapy target, the development of anti-Met antibodies has proven challenging because Met-targeting antibodies are prone to trigger downstream signaling, resulting in accelerated cancer cell proliferation. 26 In the present study, we first demonstrate that 5D5, a previously developed Met-targeting antibody, while functioning as an antagonist through the induction of Cblmediated Met degradation, also acts agonistically by activating oncogenic signaling in lung, gastric and renal cancer cells. In contrast, we have identified a novel antibody, SAIT301, which promotes Met degradation in a Cbl-independent manner but exhibits minimal agonism.
Our study thus reveals an alternative Cbl-independent Met downregulation mechanism that employs LRR and immunoglobulin-like domain-containing protein 1 (LRIG1)-mediated Met degradation. We demonstrate that SAIT301-mediated Met degradation is ubiquitin-independent and distinct from the Cbl pathway. To our knowledge, this is the first report on antibody-induced interaction of LRIG1 and Met and its subsequent degradation in the lysosomal compartment. While Cbl-dependent destabilization of Met is dictated by receptor activation, LRIG1 pathway does not require receptor activation for its function, decoupling Met signaling and its downregulation mechanism. [27] [28] [29] Consistent with this hypothesis, SAIT301-mediated Met degradation did not induce significant agonism, further supporting an enhanced therapeutic potential of SAIT301.
Met overexpression has been implicated in the development of resistance to EGFR-targeted therapies such as cetuximab. 30 To investigate this phenomenon, we tested SAIT301 in soft agar ex vivo clonogenic assay using patient-derived tumor samples that demonstrate gene amplification and overexpression of Met and reduced expression of Cbl. Consistent with its proposed Cblindependent Met degradation mechanism, SAIT301 was able to inhibit the growth of cetuximab-resistant tumors. These data suggest a potential application of Cbl-independent Met degradation mechanism in developing antibody therapeutics that overcome resistance to EGFR-targeted therapy.
RESULTS

SAIT301
, a humanized anti-Met antibody, downregulates Met without triggering downstream signaling SAIT301 is a humanized anti-Met antibody that was originally developed from mouse immunization with Met ECD. 31 To determine antibody-mediated downregulation of Met, we measured the total Met levels in NCI-H441 lung cancer cells upon treatment with SAIT301 or with the previously reported Met-targeting antibody, 5D5 (Figure 1a ). While both antibodies similarly reduced Met protein levels, Met signaling profiles by these antibodies were substantially different. Phosphorylation of Akt and Erk, major downstream signaling mediators of Met RTK, were significantly increased by treatment with 5D5. In contrast, SAIT301 demonstrated minimal agonism as shown in Figure 1b . Consistent with this observation, treatment with SAIT301 led to a reduction of Met and dosedependent growth inhibition of MKN45 gastric cancer cells (Figures 1c and d) . However, 5D5 failed to inhibit the proliferation of MKN45 cells despite its activity promoting Met degradation.
5D5 reduces Met degradation through a Cbl-dependent mechanism Cbl is known to be a major negative regulator of RTKs including Met. Upon activation, the Y1003 site in the juxtamembrane domain of Met is phosphorylated, creating a direct docking site for Cbl. To test whether SAIT301 and 5D5 initiate Met degradation by this Cbl-mediated mechanism, the interaction between Met and Cbl was measured by co-immunoprecipitation assays. Whole lysates of NCI-H441 cells after incubating with SAIT301 and 5D5 were immunoprecipitated using Met conjugated agarose beads. Whereas 30 min of 5D5 treatment increased Cbl recruitment, SAIT301 did not trigger Met and Cbl binding (Figure 2a) . Agarose beads unconjugated with antibody were used as controls (data not shown). These data suggest that 5D5 induces Met degradation through a Cbl-dependent manner whereas SAIT301 functioned independently of Cbl. Accordingly, 5D5 was unable to induce Met degradation in EBC1 lung cancer cells where Cbl expression is very low, whereas SAIT301 retained its activity promoting Met degradation and inducing cell growth inhibition (Figures 2b-d) .
PHA-665752 is a small molecule inhibitor that specifically targets Met and inhibits the phosphorylation of Met. SAIT301-initiated Met degradation was unaffected by PHA-665752. Interestingly, however, when Met kinase activity was inhibited, Met degradation activity of 5D5 was completely abolished, suggesting that Cbl-mediated Met degradation requires receptor activation (Figure 2e ).
The efficacy of SAIT301 is independent of Cbl E3 ligase activity Cbl binds to activated Met and has a role in receptor downregulation, acting as an E3 ubiquitin ligase. After HGF ligandbinding, Cbl binds to the Y1003 site of Met and induces its polyubiquitination. As shown in Figures 3a and b , treatment of EBC1 and NCI-H441 cells with 5D5 dramatically increased the polyubiquitination of Met. In contrast, SAIT301 did not induce receptor polyubiquitination in these cell lines (Figures 3a and b) . To further confirm that Met degradation by SAIT301 is Cblindependent, Cbl was depleted with small interfering RNA (siRNA) (Figure 3c ). Upon knockdown of Cbl expression, SAIT301 still reduced Met protein levels, confirming the Cbl-independent mechanism of Met degradation by SAIT301. However, 5D5-mediated degradation of Met was almost completely reversed by Cbl. Cbl knockdown by siRNA was validated by checking mRNA levels ( Figure 3d ). In addition, SAIT301 remained active when cells were treated with MG132, a proteasome inhibitor, further supporting Cbl-independent degradation of Met by SAIT301 antibody (Figure 3e ).
Previously, splice mutations of exon 14 have been associated with a deletion of the juxtamembrane domain of Met resulting in the loss of interaction with Cbl. 10 To further evaluate Cbl-independent Met degradation mechanism, we employed Hs746T, a gastric cancer cell line that harbors such an exon 14 splice mutation. As shown in Figures 3f and g, SAIT301 demonstrated both potent growth inhibition and dramatic pro-apoptotic effect in this cell line whereas 5D5 exhibited no such effects. Taken together, these experimental results implicate a novel mechanism of Cbl-independent Met degradation by SAIT301. SAIT301 induces Met degradation through a LRIG1-mediated pathway LRIG1 was discovered as a negative regulator of RTKs and has been reported to enhance the recruitment of Cbl to the EGFR. 32, 33 However, it is also demonstrated that LRIG1 functions in a Cblindependent manner to downregulate Met. 29 To determine whether LRIG1 is implicated in SAIT301-induced Met degradation, we tested the SAIT301-induced interaction between LRIG1 and Met. Interestingly, SAIT301 enhanced Met binding with LRIG1 in EBC1 and HEK293 cells as compared with 5D5 whereas the level of Cbl binding to Met was not increased by SAIT301 at the same time ( Figure 4a and Supplementary Figure 1a ). To further investigate the implication of LRIG1 in SAIT-mediated Met degradation, we employed siRNAs for LRIG1. Met degradation induced by SAIT301 was recovered by LRIG1 knockdown in Hs746T cells (Supplementary Figures 1b and c) . Moreover, LRIG1 knockdown nullified SAIT301-mediated cell apoptosis in Hs746T cells harboring the exon 14 splice mutation (data not shown). These results suggest an alternative role for LRIG1 in the antibody-mediated downregulation of Met. Furthermore, as measured by annexinV-based FACS analysis, SAIT301 significantly induced apoptotic activity of EBC1 cells (Figure 4b) , and siRNA directed against LRIG1 substantially decreased both SAIT301-mediated cell apoptosis as well as Met degradation in EBC1 cells (Figures 4c and d) . Treatment with concanamycin, an inhibitor of lysosome, reduced SAIT301-mediated Met degradation confirming that SAIT301-induced Met degradation is mediated by LRIG1 through a lysosomal pathway (Figure 4e ). In the immunocytochemistry assay, SAIT301 induced significant internalization of Met and colocalized with a lysosomal marker in EBC1 and MKN45 cells (Figure 4f ). Internalized Met also colocalized with LRIG1 in EBC1 and MKN45 cells (Figures 4g and h ). Taken together, these data indicate that SAIT301 downregulates endogenous Met through a LRIG1-dependent lysosomal pathway.
SAIT301-mediated Met degradation and tumor growth inhibition in Cbl negative tumors in vivo
Met controls the proliferation, invasion and metastasis of cancer cells. 34, 35 A cell migration assay using a xCelligence DP system (Roche Diagnostics, Penzberg, Germany) was performed in order to evaluate the function of SAIT301 in cancer cell migration. Although treatment with 5D5 showed a slight increase in EBC1 migration, SAIT301 significantly inhibited the migration of EBC1 cells, which have low levels of Cbl (Figure 5a ). Treatment with SAIT301 suppressed the migration of Hs746T by B70% as compared with medium controls in the absence or presence of HGF (Figure 5b ). However, 5D5 promoted cell migration by two-fold in the absence of HGF. It implicates that 5D5 enhances the Met signaling pathway and subsequent cancer cell migration. In conclusion, these results confirm that SAIT301 inhibits cancer cell migration by downregulating Met in a Cbl-independent manner.
Next, we assessed the in vivo antitumor effect of SAIT301 using nude mouse heterotopic xenograft models. Animals received a subcutaneous injection of EBC1 or Hs746T cells and were randomized 7 days after the inoculation for antibody treatment. Five mg/kg, three doses, of SAIT301 or 5D5 were given intravenously (IV) once a week. SAIT301 demonstrated a strong inhibition of tumor growth, resulting in the reduction of tumor volume by 77% in EBC1 model (Figure 5c ), and even inducing a regression of the tumor in Hs746T model (Figure 5d ). In comparison, 5D5 treatment resulted in much less tumor growth inhibition. Furthermore, in EBC1, we found that total Met protein levels from the tumor extract were substantially reduced by SAIT301 treatment (Figure 5e ) (we were not able to study the correlation in Hs746T, since SAIT301 treatment caused almost complete regression of the tumor). This result is consistent with the reduced Ki67 staining in the tumor tissues indicating inhibition of tumor cell proliferation by SAIT301. In addition, SAIT301 treatment decreased angiogenesis, evident from decrease in CD31 positive areas (data not shown). As previously discussed, EBC1 and Hs746T cells display abnormal Cbl function, yet SAIT301 was able to inhibit tumor growth in both instances.
These findings further support the idea that SAIT301 induces Met degradation in a Cbl-independent manner. SAIT301 has Cbl-independent Met antagonistic activity in tumors resistant to EGFR-targeted therapy To evaluate antitumor activity of SAIT301 and implication of LRIG1 in antibody-mediated Met degradation, a soft agar ex vivo clonogenic assay was performed using 14 patient-derived lung cancer cells. As described in the previous report by Krumbach et al. 31 , lung tumor #1 is an example of a cetuximab-sensitive tumor, while #2 and #3 are among the cetuximab-resistant tumor varieties. Lung tumors #2 and #3 had the highest levels of Met expression as well as Met activation among the 14 samples. SAIT301 had no effect on the clonogenic growth of tumor #1; however, clonogenic growth of tumors #2 and #3 were substantially reduced by SAIT301 (Figure 6a) . Interestingly, tumors #2 and #3 showed very low levels of Cbl expression as measured by western analysis whereas all three tumors express wild-type Met without deletion (Figures 6b and c) . These data suggest a plausible correlation of cetuximab resistance and low Cbl expression in conjunction with elevated Met expression, and potential value of Cbl-independent Met degradation by SAIT301 in overcoming EGFR resistance.
DISCUSSION
The development of bivalent anti-Met antibodies has proven challenging, as bivalency often causes various degrees of agonism. 26 Despite these difficulties, we have generated an efficacious bivalent humanized monoclonal antibody with low agonism. In the present study, we have shown that while SAIT301 has a strong suppressive effect on tumor growth and induces almost complete degradation of Met; this novel therapeutic antibody exhibits minimal agonism as compared with the 5D5 antibody.
As treatment with 5D5 downregulates Met partially while exhibiting agonism, we hypothesized that this regulation may have occurred in Cbl and HGF/SF-dependent manner. Immunoprecipitation of Met after treatment with 5D5 confirmed an interaction between Met and Cbl, but such an association was not observed with SAIT301. In addition, Cbl knockdown completely abolishes 5D5-mediated Met degradation. These results suggest that binding of the agonistic 5D5 antibody to Met results in Met degradation mainly via Cbl-mediated polyubiquitination, whereas SAIT301-induced Met degradation is not dependent on Cblmediated proteasomal pathway.
We then sought to identify alternate pathway responsible for SAIT301-induced Met degradation. LRIG1-mediated lysosomal pathway and ADAM-10-mediated shedding pathway have been described as alternate regulatory pathways for Met degradation. 29, [36] [37] [38] [39] We first observed that SAIT301 did not induce shedding of Met surface receptor that was determined by measuring the amount of shed Met in the cell culture media following SAIT301 treatment (data not shown). Interestingly, however, SAIT301 induces Met degradation via a LRIG1-mediated pathway, a conclusion supported by results from two different tumor cell lines. First, we tested the effect of SAIT301 on a Met overexpressing EBC1 lung cancer cell line, which has high LRIG1 levels but very low Cbl. Treatment with SAIT301 promoted the binding between Met and LRIG1, and when LRIG1 was knocked down, SAIT301-induced Met degradation and cellular apoptosis was significantly decreased. Furthermore, the lysosomal inhibitor concanamycin reversed the LRIG1-dependent Met degradation as induced by SAIT301, consistent with the hypothesis that LRIG1 utilizes lysosomal pathway to degrade Met. 29 Not surprisingly, SAIT301 showed a strong antitumor activity against the EBC1 lung cancer cell line in both in vitro and in vivo settings. Recently, Greenall et al. 40 reported the discovery of two nonagonistic bivalent antibodies (LMH 87 and LMH 88) that promote Met internalization/degradation and inhibit tumor growth both in vitro and in vivo, which is very similar to our findings. However, we noticed that the epitope of SAIT301 (data not shown) is different from that of LMH 87. Further studies would be required to see if LMH 87 and SAIT301 share the molecular mechanism of inhibition of Met signaling.
The Hs746T gastric cancer cell line is another interesting cell line that has an exon 14 deletion in the MET gene resulting in Met that does not interact with Cbl. 41 In this Met-mutated cell line, SAIT301 prevents cell migration and cellular growth in vitro, and almost completely regresses tumors in a heterotopic xenograft model using this Hs746T cell line, again supporting the conclusion that SAIT301 acts independently of any Cbl-mediated mechanism.
EGFR tyrosine kinase inhibitors, such as erlotinib and gefitinib, have revolutionized the treatment of non-small cell lung cancers. 42, 43 Although these drugs prolong survival of EGFRmutated lung cancer patients, most patients ultimately acquire resistance to EGFR tyrosine kinase inhibitors. One of the mechanisms by which the tumor cells develop EGFR tyrosine kinase inhibitors resistance is by overexpressing Met. 30 We have identified two cases of patient-derived lung tumors among 14 cases where resistance to EGFR-targeting drug was brought on by EGFR downregulation and Met overexpression, while Cbl was also downregulated. In these tumors, monotreatment with SAIT301 was sufficient to block tumorigenesis supporting a Cblindependent Met degradation mechanism of SAIT301 antibody. While more studies are warranted, it is conceivable that the majority of lung cancer cells will eventually become resistant to EGFR-targeted therapy by downregulating both EGFR and Cbl, as Cbl is involved in negative regulation of both EGFR and Met. 15 In this case, anti-Met antibody that degrades Met through Cbl-dependent mechanism will not have any treatment benefit despite the high levels of Met expression in the tumor. SAIT301, in contrast, is proposed to be able to overcome the resistance to EGFR-targeted therapy by a Cbl-independent Met degradation.
These results also raise intriguing questions regarding the structural biology of Met signal transduction. Our findings suggest that SAIT301, while it clearly binds to an extracellular Met epitope, generates an intracellular signal that is distinct from that resulting from the binding of other antibodies such as 5D5. The molecular mechanism underlying such bifurcating signaling is not clear; it is plausible to speculate that the transmembrane domain is capable of transmitting at least two different conformational changes resulting in differential degradation mechanism. While we are actively pursuing structural studies that might explain some of these interesting results in molecular aspects of receptor signaling and its regulation, they are beyond the scope of this paper and remain further elucidated.
In summary, we have identified a novel bivalent Met-targeting antibody that promotes Met degradation by a Cbl-independent degradation pathway. Notably, SAIT301 has minimal agonism due to its implication in Cbl-independent Met degradation. This enhanced efficacy suggests a role for SAIT301 in the treatment of cancers in which Met has a pathologic function. Furthermore, this unique mode of action makes SAIT301 an attractive agent in treating a subset of lung cancer patients whose tumors have developed resistance to EGFR targeting agents via Cbl downregulation. We are currently evaluating whether SAIT301 treatment is useful in overcoming EGFR-targeting drug resistance in other tumor types.
MATERIALS AND METHODS
Antibodies, reagents and cell lines
The following commercially available antibodies were used: mouse IgG (eBiosciences, San Diego, CA, USA), Met, LRIG1 (Abcam, Cambridge, UK), Akt, p-Akt (S473), Cbl, p-Erk and GAPDH (14C10) antibodies (Cell Signaling, Danvers, MA, USA). PHA-665752 and erlotinib were purchased from Selleck Chemicals (Houston, TX, USA), siRNAs of LRIG1 and Cbl were purchased from Qiagen (Courtaboeuf, France) and Dharmacon (Epsom, UK) and 5D5 was derived from HB-11895 purchased from ATCC (Rockville, MD, USA). Human gastric carcinoma MKN45 (JCRB0254) and EBC1 (JCRB0820) cell lines were purchased from the Health Science Research Resource Bank (Osaka, Japan). Caki-1 renal carcinoma cell lines (HTB-46), Hs746T gastric cancer cell lines (HTB-135) and NCI-H441 human lung adenocarcinoma cell lines (HTB-174) were purchased from the ATCC.
ELISA for Met degradation assay
Total Met was analyzed by a sandwich ELISA. For the sandwich ELISA, total Met levels in cell lysate were determined using human total HGF R/c-Met ELISA kit (R&D systems, Minneapolis, MN, USA). All assays were performed as recommended by the manufacturers.
Cell proliferation assay
Cell proliferation in response to antibody treatment in vitro was assessed by a CCK-8 (Dojindo Laboratories, Tokyo, Japan) assay according to manufacturer instructions. Hs746T cells and EBC1 cells were plated at a density of 3 Â 10 3 cells and MKN45 were plated at a density of 1 Â 10 4 cells per well in FBS 10% (v/v) RPMI 1640 medium onto a 96-well plate (BD Biosciences, Palo Alto, CA, USA). After 24 h incubation, 10 ml of antibodies diluted in 10% FBS (v/v) RPMI medium were added. After 72 h incubation, 10 ml of the CCK-8 reagent was added to each well followed by incubation at 37 1C for 2 h. The absorbance was measured using a microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 450 nm with a reference wavelength 650 nm.
Cell apoptosis assay
Caspase 3/7 Glo luminescent assay was used to assess tumor cell apoptosis in response to antibody treatment in vitro. Briefly, EBC1 cells in FBS 10% (v/v) RPMI1640 medium and Hs746T cells in FBS 10% (v/v) DMEM medium were plated onto a black 96-well plate with clear bottom (Corning Incorporated, Lowell, MA, USA) at a density of 5 Â 10 3 cells per well, followed by treatment with antibodies diluted in 10% FBS containing medium. After incubation for 72 h, 100 ml of the Caspase 3/7 Glo solution (Promega, Madison, WI, USA) was added to each well followed by incubation at room temperature for 30 min. The luminescence signal was recorded using Envision 2104 Multi-label Reader (Perkin Elmer, Foster City, CA, USA). The cell apoptotic rate was normalized by the CCK-8 or CTG assay value measuring cellular growth.
Immunofluorescence and confocal microscopy For live cell image, SAIT301 was conjugated with Alexa Flour 647 using a protein-labelling kit (Invitrogen, Carlsbad, CA, USA). MKN45 and EBC1 cells were incubated with 1 mg/ml of fluorescence-conjugated SAIT301. After incubation for 4 h, NucBlue live cell stain (Invitrogen) and Lysotracker DND-99 (Invitrogen) were added to cells. Immunofluorescent images were acquired using a LSM710-confocal microscope (Carl Zeiss, Jena, Germany). For preparing the fixed cell image, the cells were fixed with 4% formaldehyde, permeabilized and blocked with 0.5% Triton X-100 and 5% Donkey serum (Jackson immune, West Grove, PA, USA) in PBS, and subjected to primary and fluorescently labeled secondary antibodies in 5% Donkey serum in PBS.
Annexin V/PI staining of apoptotic cells EBC1 cells were harvested from culture plates and centrifuged at 4 1C, 1200 r.p.m for 3 min and then stained with 5 ml of Annexin V-APC (BD pharmingen, San Jose, CA, USA) and 2 ml of PI (propidium iodide, 50 mg/ml) for 15 min at dark condition. Stained cells were analyzed by FACS CantoII flow cytometer (Becton-Dickinson, Mountainview, CA, USA).
Cell migration assay
Migration assay was tested with CIM-plate 16 in the xCelligence DP system. In the upper chamber, 5 Â 10 4 or 10 5 cells were seeded in 100 ml culture medium without FBS. The lower part of CIM-plate 16 were filled with growth medium supplemented with 10% FBS as a chemoattractant. To determine the effect of HGF, 200 ng/ml HGF were added with 10% FBS in lower chambers. Migration of the cells was measured by changes of the impedance signal detected on the backside of 8-mm pore membrane.
Cell migration assay using 96 well plates with stopper EBC1 cells were plated onto a 96 well black plate with stopper (Platypus, Oxon, UK) at a density of 8 Â 10 4 cells per well, then incubated for 24 h. After removing the stopper, the cells were treated with 1 mg/ml of antibodies diluted in 10% FBS containing medium. After incubation for 48 h, 100 ml of the Calcein AM solution (BD Biosciences) was added to each well followed by incubation at 37 1C for 30 min. The fluorescence signal was detected using fluorescence microscopy (Carl Zeiss).
Tumor xenograft study
To study the effect of Met antibodies on tumor growth in vivo, tumor xenograft studies were performed using 5-6 weeks old male BALB/c Nude mice. Mice were acclimated for at least a week before they received tumor inoculation. For both EBC1 and Hs746T xenograft models, 5 million cells in 200 ml of serum-free media/matrigel (50:50 v/v) was injected subcutaneously into the right flank region of the mice under anesthesia by 1-2% isoflurane. After 7 days, when the average tumor size was close to 100-200 mm 3 , mice were randomized into the following treatment groups: 5D5 (5 mg/kg IV once a week), SAIT301 (5 mg/kg IV once a week), and vehicle (PBS 0.2 ml IV once a week). Each treatment group consisted of 15 mice. Tumor volumes and body weights were measured two to three times a week for total study period about 4 weeks. The tumor volume (V) was calculated as follows: V (mm 3 ) ¼ {long axis length (mm) Â (short axis length (mm)) 2 }/2. At the end of the in vivo phase, the mice were euthanized and the tumors were extracted and fixed in 10% formaldehyde or flash frozen.
Analysis of the splice mutation of the Met gene 
